ADSTILADRIN® (nadofaragene firadenovec-vncg) logo

This site is intended for US healthcare professionals.

Request a Rep
ADSTILADRIN® (nadofaragene firadenovec-vncg) logo
Click to toggle navigation menu.

The first and only FDA-approved intravesical gene therapy for high-risk NMIBC

Learn more

Nadofaragene firadenovec-vncg (ADSTILADRIN) is a recommended treatment option in the
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1*
Tumor cells icon

A unique way to treat

Attacks tumor cells directly while simultaneously activating the innate and adaptive arms of a patient’s immune system to continually fight back2

Administration bottle icon

Intravesical instillation

A simple, ready-to-use formulation administered in the urology office2

Dosing schedule icon

Convenient dosing schedule

Once every 3 months, minimizing dosing  frequency2

Read more

*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer V.2.2023. © National Comprehensive Cancer Network, Inc 2023. All rights reserved. Accessed May 2, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Abbreviations: BCG, Bacillus Calmette-Guérin; CIS, carcinoma in situ; NMIBC, non–muscle-invasive bladder cancer.
NCCN, National Comprehensive Cancer Network® (NCCN®).

Sign up to receive information and updates on ADSTILADRIN

Your Information

Your Mailing Address

Interested in becoming a treatment site?*

Radio(Required)
By providing the information requested, I am giving Ferring permission to store and use the information that I have provided. I understand and agree that my information will be used by Ferring (or companies working on Ferring’s behalf) to contact me by telephone, email, or mail to provide me with information that may be of interest to me or to invite me to participate in research, educational, and marketing initiatives. I understand that my information will be treated as described in Ferring’s Privacy Notice, which provides details about my privacy rights. Also, I understand that I may opt out of the database at any time by making the request at Data Subject Form or by calling 1-844-NADONOW (1-844-623-6669), Monday through Friday, 9 AM to 6 PM ET to speak to a representative or leave a voicemail. This statement may be updated from time to time.(Required)
*Required field.

References: 1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): bladder cancer, version 2.2023. April 25, 2023. Accessed May 2, 2023. https://www.nccn.org/guidelines/guidelines-with-evidence-blocks​ 2. ADSTILADRIN. Package insert. Ferring Pharmaceuticals, Inc; 2022.

Important Safety Information

INDICATION

ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.

WARNINGS AND PRECAUTIONS

  • Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.
  • Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.

DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.

USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.

ADVERSE REACTIONS: The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING.

Please see full Prescribing Information for ADSTILADRIN.

Close popup

Are you a US healthcare professional?

Yes No
Supply Status

ADSTILADRIN supply information

We remain committed to ensuring widespread availability of ADSTILADRIN as early as possible and are therefore scaling up our manufacturing efforts to increase supply.

If you are interested in receiving supply updates, please sign up here.